NCT00747578 Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan Status UNKNOWN Phase N/A
NCT00739050 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Status TERMINATED Phase PHASE4
NCT00732940 Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) Status TERMINATED Phase PHASE2
NCT00724867 A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States Status COMPLETED Phase PHASE3
NCT00723671 Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus Status COMPLETED Phase NA
NCT00712933 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 Status COMPLETED Phase PHASE3
NCT00684255 Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) Status TERMINATED Phase PHASE1
NCT00671047 The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study Status UNKNOWN Phase N/A
NCT00668330 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Status COMPLETED Phase PHASE4
NCT00660881 Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Status COMPLETED Phase PHASE2
NCT00657007 Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Status COMPLETED Phase PHASE1
NCT00626197 A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) Status TERMINATED Phase PHASE3
NCT00624351 Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease Status COMPLETED Phase PHASE2
NCT00594932 Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis Status COMPLETED Phase PHASE1/PHASE2
NCT00583362 A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02 Status COMPLETED Phase PHASE2